Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.

Takeda Pharmaceuticals Inc. struck a more somber tone in 2024, undergoing a “significant, multiyear efficiency program” to navigate short-term generic competition and get back to ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...